Brief: NeuroMetrix Reports That Quell Technology Is To Be Evaluated For Neuromyelitis Optica Spectrum Disorder

NeuroMetrix

15/06/2021 14:36

June 15 (Reuters) - NeuroMetrix Inc  NURO.O :
    * NEUROMETRIX REPORTS THAT QUELL® TECHNOLOGY IS TO BE
EVALUATED
FOR NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD) IN A
RANDOMIZED CONTROLLED TRIAL
    * NEUROMETRIX INC - CURRENT TRIAL WILL ENROLL 46 PATIENTS
WITH
NMOSD

Source text for Eikon:  ID:nGNXb1Y9Y3 
Further company coverage:  NURO.O 

 ((Reuters.Briefs@thomsonreuters.com;))